CULLINAN THERAPEUTICS, INC.

Analyst Reco. Cullinan Therapeutics, Inc.

Equities

CGEM

US2300311063

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
28.1 ^USD	+4.04%		+48.76%	+175.76%

29/04	Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	MT
29/04	Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CULLINAN ONCOLOGY : Morgan Stanley Adjusts Cullinan Oncology's Price Target to $43 From $40, Maintains Overweight Rating	07/21/07	MT
CULLINAN ONCOLOGY : HC Wainwright Adjusts Cullinan Management PT to $55 From $48, Maintains Buy Rating	04/21/04	MT
CULLINAN ONCOLOGY : SVB Leerink Adjusts Price Target on Cullinan Management to $54 From $48, Maintains Outperform Rating	04/21/04	MT
CULLINAN ONCOLOGY : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target	27/21/27	MT
CULLINAN ONCOLOGY : Morgan Stanley Adjusts Price Target on Cullinan Management to $40 From $38, Maintains Equal-Weight Rating	19/21/19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer